**Original Article**

Detection of Different Types of Metallo-β-Lactamases among Pseudomonas aeruginosa Isolates Obtained from Intensive Care Unit Patients


1Department of Infectious Diseases, Nosocomial Infection Research Center, Isfahan University of Medical Sciences, Isfahan, Iran;  
2Department of Infectious Diseases, Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran;  
3Department of Infectious Diseases, Isfahan University of Medical Sciences, Isfahan, Iran;  
4Department of Microbiology, Science and Research, Islamic Azad University, Shiraz, Iran;  
5Department of Infectious Diseases, Acquired Immunodeficiency Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.

Received Mar 14, 2015; accepted May 20, 2015

**Introduction:** Pseudomonas aeruginosa is a serious challenge for antimicrobial therapy, due to chromosomal mutations or intrinsic resistance to various antimicrobial agents, such as Metallo-β-Lactams (MBL). This study aimed to investigate the prevalence of β-lactamases encoding genes among P. aeruginosa strains isolated from intensive care unit (ICU) patients by phenotypic and multiplex PCR methods. **Methods:** A total of 48 non-duplicate strains of P. aeruginosa were collected from different clinical specimens of patients hospitalized in ICU wards of a teaching hospital in Isfahan, Iran. Susceptibility test was performed by disk diffusion method. All meropenem resistant strains were subjected to modified Hodge test (MHT) for detection of carbapenemases. Multiplex PCRs were performed to detect β-lactam-resistant P. aeruginosa isolates. **Results:** In disk diffusion method, P. aeruginosa strains showed the most (97.9%) resistance against imipenem and meropenem and the least (45.8%) against colistin. Thirty-six (75%) out of the 48 isolates were multidrug resistant. PCR amplification of β-lactamases genes showed the presence of blaVIM genes in 7 (14.6%) and blaIMP in 15 (31.3%) strains. Also, blaOXA, SPM, GIM, AIM and NDM genes were not observed in any of the strains. We only found a statistically significance difference between the presence of blaIMP gene and multidrug-resistant (MDR) positivity and source of specimen (p=0.009 and 0.002, respectively). **Conclusion:** Rapid and reliable identification of MBLs appears to be necessary for effective treatment of related infections. Besides, our results may provide useful perception to make a more appropriate choice of antibiotics, which may put a stop to carbapenem-resistant infections. J Med Microbiol Infe Dis, 2014, 2 (2): 84-90.

**Keywords:** Pseudomonas aeruginosa, PCR, Carbapenem, Beta-lactamase.

**INTRODUCTION**

Pseudomonas aeruginosa is widely known as an opportunistic invader rather than a cause of primary infection in healthy subjects [1]. P. aeruginosa causes approximately 10% of nosocomial infections with a high mortality rate. The complete sequencing of a wild-type P. aeruginosa strain has provided useful information on not only to its pathogenicity, but also to its potential for resistance to many antibiotic agents and the development of increased multidrug resistance (MDR) in healthcare settings [2, 3].

Currently, the emergence of carbapenemase producing strains is noticeable among Enterobacteriaceae, such as Pseudomonas spp. [4]. Carbapenems are drugs of choice for the treatment of infections caused by penicillin- or cephalosporin-resistant Gram-negative and nonfermenting bacilli, such as P. aeruginosa and Acinetobacter spp. [1].

The Metallo-β-lactamase (MBL) producing strains are often resistant to aminoglycosides and fluoroquinolones, but susceptible to polymyxins. MBL producing P. aeruginosa strains are the cause of several nosocomial outbreaks in tertiary centers worldwide, exhibiting the necessity of an appropriate infection control strategy. Also, these isolates cause serious infections, such as septicemia and pneumonia and are associated with failure of treatment with carbapenems [5, 6].

**Correspondence:** Mohammad Reza Yazdani  
Department of Infectious Diseases, Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Hezar Jarib St., Isfahan, Iran, 8174673461.  
Email: yazdani@med.mui.ac.ir

**Tel:** +98 (311) 33359359  
**Fax:** +98 (311) 33373735

http://jommid.pasteur.ac.ir
Carbenem resistance can occur, and it involves different mechanisms in *P. aeruginosa*, such as reduced outer membrane permeability, increased energy-dependent efflux, porin down regulation, and production of carbenem-hydrolyzing enzymes [1]. In addition, most of the carbenemase genes are plasmid carried and easily transferable between various bacterial species and genera [7].

Carbenems (meropenem and imipenem) are effective against Gram-negative MDR strains [8]. Current data propose that carbenem resistance is increasing among isolates of *P. aeruginosa* [3]. MBL producing strains hydrolyze all carbenems, and deficiency of these enzymes can result in resistance to imipenem and reduced sensitivity to meropenem [9].

In the last decade, various classes of β-lactamases (A, B, and D) have been identified in *P. aeruginosa* [10]. The carbenemases found, are mostly different types of MBLs, such as TIM, SME, GIM, IMP, NDM, SPM, and VIM. The frequency of these types has increased in *P. aeruginosa* worldwide [1].

Nosocomial outbreaks caused by MBL-producing *P. aeruginosa* have been reported in many countries worldwide [11]. Carbenemases that hydrolyze carbenems and make them inactive have been progressively reported in Asia, Europe, Canada, and the United States [12].

Various current studies from different parts of our country revealed an increased frequency of MBL-producing *P. aeruginosa* in different hospital units [13].

Several phenotypic and genotypic tests have been carried out to confirm carbenem resistant cases. Among phenotypic tests, the modified Hodge-test (MHT) is an easy test to perform, but it is not recommended for non-fermenters [5, 12].

Identification of genes coding for carbenem resistance by PCR, usually provides reliable and accurate results, but application of this method is limited to clinical laboratories due to the cost [1].

Single or multiplex PCR assays require expert knowledge of carbenemases epidemiology and these methods are typically focused only on prevalent carbenemase genes [14].

Assessment of phenotypic and genotypic characteristics of these isolates would be necessary for understanding the resistance mechanisms and their potential spread. We designed this study to determine the prevalence of MBL-producing *P. aeruginosa* (the presence of TIM, SME, GIM, IMP, NDM, SPM, and VIM) among *P. aeruginosa* strains isolated from intensive care unit (ICU) patients in Al-Zahra Hospital of Isfahan, Iran.

**MATERIAL AND METHODS**

**Bacterial identification.** In a retrospective cross-sectional study, a total of 48 non-duplicate isolates of *P. aeruginosa* were collected from clinical specimens of patients hospitalized in ICU wards of Al-Zahra hospital of Isfahan City, Iran, from March 2012 to April 2013. These isolates were obtained from culture of specimens from tracheal aspirate, blood, urine, wound, catheter, and peritoneal fluid of the patients.

Bacteria were identified as *P. aeruginosa* by biochemical tests or based on the following characteristics: Gram-negative bacilli, citrate positive, non-fermentative, TSI Alk/Alk, motile, H₂S negative, urease negative, oxidase positive, and catalase positive. PCR amplification was performed to verify these isolates with *P. aeruginosa* specific primers (primer sequence: gyr B-F: 5’-CTTGACCATCCTGCAGAAC-3’, gyr B-R: 5’-CGCAGCAGATGCGCGACCC-3’) with product size 222 bp [15]. The confirmed isolates were kept at -70°C. Standard strain *P. aeruginosa* ATCC 27853 was used as control [3].

**Antimicrobial susceptibility testing.** Antibiotic susceptibility testing was performed for all collected *P. aeruginosa* isolates by disk diffusion method on Mueller-Hinton agar (Merck, Germany). Susceptibility was defined according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [14]. Antibiogram disks containing meropenem (MEM: 10 μg), imipenem (IPM: 10 μg), ceftazidime (CAZ: 30 μg), cefepime (FEP: 30 μg), amikacin (AK: 30 μg), ciprofloxacin (CIP: 5 μg), colistin sulphate (10 μg), ampicillin/sulbactam (20 μg), and cefotaxime (CTX: 30 μg) (MAST, Bottle, Merseyside, UK), were used to test antimicrobial susceptibility. If an isolate was resistant to three or more classes of antibiotics (including penicillins/cephalosporins, carbenems, aminoglycosides, and fluoroquinolones), it was regarded as MDR [16]. *P. aeruginosa* ATCC 27853 and *Escherichia coli* ATCC 25922 were used as reference strains in susceptibility test [3, 17].

**Modified Hodge test.** The MHT was performed for all of the meropenem resistant isolates (i.e. inhibition zone: 16-21 mm) for detection of carbenemases. Briefly, a 1/10 dilution of an inoculum of the indicator organisms, adjusted to a 0.5 McFarland turbidity standard, was used to inoculate by swabbing the surface of Mueller-Hinton agar (Hi-Media, India) plates. Then, a meropenem disk (MEM: 10 μg; MAST, Bootle, Merseyside, UK) was placed on each plate. An overnight grown single colony of the isolate was inoculated onto the plates. The presence of an inhibition zone due to carbenemase production by the test strain was considered as positive. Besides, combined-disk (CD) tests with boramic acid and EDTA were performed for detection of class A carbenemases and MBLs, respectively. In MBL-producing strains, the difference of inhibition zone between carbenem disk and carbenem-EDTA disk was ≥7 mm) [5, 18, 19].

**Extraction of total DNA.** For molecular identification, total DNA content of each isolate was extracted using a modified boiling method. Briefly, a single colony from a 16-hour culture on the nutrient agar (Hi-Media, India) was suspended in 50 μl of TES buffer [50 mM Tris hydrochloride (pH 8.0), 5 mM EDTA, 50 mM NaCl], and the suspension was heated at 95°C for 10 min and placed at room temperature for 5 min. Then it was centrifuged at 14,000 rpm for 10 min at 4°C. DNA-containing supernatant
was transferred to new sterile DNase free-RNase free microtubes [20].

Rapid detection of AIM, SME, GIM, IMP, NDM, SPM, and VIM Genes by Multiplex PCR. Multiplex PCR was performed for amplification of AIM, SME, GIM, IMP, NDM, SPM, and VIM genes of P. aeruginosa, using the primers listed in Table 1 according to the previous protocols [21]. Two multiplex reactions were designed; one was detection of blaIM, blavIM and blasME, and the other was detection of blasDM, blasAM, blasPM, and blasDM.

Two µL of total DNA was subjected to multiplex PCR in a 50-µL reaction mixture. The mix for the detection of blaIM, blavIM, and blasME genes contained 1× PCR buffer [10 mmol/L Tris–HCl (pH 8.3), 50 mmol/L KCl], 1.5 mmol/L MgCl₂, 0.125 mmol/L of each deoxynucleotide triphosphate, 10 µmol/L of each primer, and 2 U of Taq polymerase (Fermentas R, Korea). The mix for the detection of blasDM, blasAM, and blasPM, blasDM genes contained 1× PCR buffer [10 mmol/L Tris–HCl (pH 8.3), 50 mmol/L KCl], 3 mmol/L MgCl₂, 0.125 mmol/L of each deoxynucleotide triphosphate, 10 µmol/L of each primer, 3 µL of dimethyl sulfoxide, and 2.5 U of Taq polymerase.

Amplification was carried out using the following thermal cycling conditions: initial DNA denaturation at 94°C for 10 min, followed by 36 cycles of denaturation at 94°C for 30 sec, annealing at 52°C for 40 sec, and extension at 72°C for 50 sec, followed by final extension at 72°C for 5 min. Agarose gel electrophoresis of the amplified DNA product with 100 bp size marker (Fermentas R, Korea) was performed for one hour at 80 V in a 2% agarose gel in 1× TAE buffer [40 mmol/L Tris–HCl (pH 8.3), 2 mmol/L acetate, 1 mmol/L EDTA] containing 0.05 mg/L ethidium bromide to detect the specific band [21]. Primers were purchased from Metabion (Munich, Germany) and other molecular materials purchased from Cinnagen, Iran. Reference strain P. aeruginosa ATCC 27853 was used as the blaMBL gene’s negative control strain.

Statistical analysis. Statistical analyses were performed using the statistical software SPSS version 18.0 for Windows (SPSS Inc., Chicago, IL). The diagram was plotted using Excel software version 2013 (Microsoft Corporation, USA). The intermediate level of susceptibility was considered as resistance in data analysis.

Continuous variables were presented as mean ± standard deviation (SD) and compared using the Student’s t-test, or expressed as the median and range. Categorical variables were compared using Chi-square test or Fisher exact test if the expected values were less than 10. All tests were two-tailed and p<0.05 was considered statistically significant.

Table 1. Oligonucleotides used in this study

<table>
<thead>
<tr>
<th>Primera</th>
<th>Sequence (5’–3’)b</th>
<th>Gene</th>
<th>Product size (bp)c</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMP-F</td>
<td>GGAATAGATGGCTTAAATCT</td>
<td>blαIM</td>
<td>232</td>
</tr>
<tr>
<td>IMP-R</td>
<td>GGTTCATGACCGAAACCAC</td>
<td>blαIM</td>
<td>271</td>
</tr>
<tr>
<td>SPM-F</td>
<td>AACAATCCGGTGAGCGAAACG</td>
<td>blαSPM</td>
<td>322</td>
</tr>
<tr>
<td>SPM-R</td>
<td>AACTATCCGCTGTAAGCACG</td>
<td>blαSPM</td>
<td>390</td>
</tr>
<tr>
<td>AIM-F</td>
<td>CTTAGGTGACCGGAACAC</td>
<td>blαAIM</td>
<td>551</td>
</tr>
<tr>
<td>AIM-R</td>
<td>GGTTCGCCCACCTGCAAACTT</td>
<td>blαAIM</td>
<td>477</td>
</tr>
<tr>
<td>VIM-F</td>
<td>GATAATGGTTGATCGCAYA</td>
<td>blαVIM</td>
<td>621</td>
</tr>
<tr>
<td>VIM-R</td>
<td>CGAATCGGCGAGCCACCA</td>
<td>blαVIM</td>
<td>673</td>
</tr>
<tr>
<td>SME-F</td>
<td>ACTTGGAGGGAGGAATGGGC</td>
<td>blαSME</td>
<td>86</td>
</tr>
<tr>
<td>SME-R</td>
<td>ACCTTCAATCCTTGATGCG</td>
<td>blαSME</td>
<td>290</td>
</tr>
<tr>
<td>NDM-F</td>
<td>CGTGTGATGGCGATCGTTTTTC</td>
<td>blαNDM</td>
<td>494</td>
</tr>
<tr>
<td>NDM-R</td>
<td>CGAATGGTCTGCACTCAAGTC</td>
<td>blαNDM</td>
<td>494</td>
</tr>
</tbody>
</table>

a F. sense primer; R. antisense primer
b Y=C or T

RESULTS

Demographic characteristics of carriers of P. aeruginosa. The medical records of the 48 index patients were reviewed. The mean age of the patients was 49.5±19.2 years, with a male to female ratio of 1.82:1. Seventeen (35.4%) patients were female and 31 (64.6%) were male. The samples were urine (n=19, 39.5%), blood (n=12, 25%), tracheal aspirate (n=11, 22.9%), wound (n=4, 8.3%), catheter (n=1, 2.08%), and peritoneal fluid (n=1, 9%). The most common underlying diseases were urinary and blood infections.

Antimicrobial susceptibility of clinical strains. The antibiotic resistance of the strains are shown in Figure 1. In the disk diffusion method, P. aeruginosa strains showed the most (97.9%) resistance against imipenem and meropenem and the least (45.8%) against colistin. Thirty-six (75%) out of the 48 isolates were MDR. Chi-square analysis showed no significant relationship between the MDR positive and MDR negative isolates (p=0.99) in terms of gender. Also, MDR and non-MDR isolates did not show any statistically significant difference in terms of source of specimen (p=0.85) and mean age (p=0.52). Frequency of MDR and non-MDR isolates as well as demographic characteristics of patients are listed in Table 2.

Testing of Bacterial isolates for the presence of AIM, SME, GIM, IMP, NDM, SPM, and VIM genes. All of the 48 P. aeruginosa isolates were verified by amplification of the gyrB gene. PCR screening was performed for all strains.
blaIMP and blaVIM genes were detected in 15 (31.3%) and 7 (14.6%) isolates, respectively. In one isolate of *P. aeruginosa* from urine, both blaIMP and blaVIM genes were detected. Positive controls of blaIMP and blaVIM (used individually or combined) produced expected bands and confirmed the specificity of the PCR primers used in simplex and multiplex PCR methods. Expected fragments were seen in multiplex PCR method (Figures 2-4). MHT or CD tests were positive for isolates with blaIMP or blaVIM genes, and all of them were MDR. Fisher exact test showed a statistically significant difference between the presence of blaIMP gene and MDR positivity (*p*=0.009). Frequency of *P. aeruginosa* isolates, having blaVIM and blaIMP genes, was determined based on demographic characteristics of patients (Table 3). Prevalence of blaIMP and blaVIM genes in male and female patients were 32.3%, 16.1%, and 29.4%, 11.8%, respectively. Chi-square analysis did not show any statistically significant difference between male and female patients in terms of the presence of these genes (*p*>0.05). The mean age of patients with blaIMP gene was lower than other patients, but this difference was not statistically significant (*p*=0.84). Ten (52.6%) out of 19 urine samples contained blaIMP. The Fisher exact test showed a significant difference between the source of specimen and the presence of blaIMP gene (*p*=0.002). We could not find any statistically significant difference between the presence of blaVIM gene and MDR positivity (*p*=0.11), mean age (*p*=0.64), and source of the specimen (*p*=0.15). Also, both multiplex and simplex PCR amplifications showed that all of the isolates were negative for blaGIM, blaSME, blaSPM, blaNDM, and blaAIM genes.

**Table 2.** Frequency of MDR and non-MDR isolates versus demographic characteristics of patients

<table>
<thead>
<tr>
<th>Parameters</th>
<th>MDR No. (%)</th>
<th>Non-MDR No. (%)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean ± SD (y)</td>
<td>49.1±17.4</td>
<td>50.4±24.8</td>
<td>0.85</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>23 (74.2)</td>
<td>8 (25.8)</td>
<td>0.99</td>
</tr>
<tr>
<td>Female</td>
<td>13 (76.5)</td>
<td>4 (23.5)</td>
<td></td>
</tr>
<tr>
<td>Isolated specimen site</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine</td>
<td>1 (100)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Catheter</td>
<td>14 (73.7)</td>
<td>5 (26.3)</td>
<td></td>
</tr>
<tr>
<td>Tracheal aspirate</td>
<td>6 (54.5)</td>
<td>5 (45.5)</td>
<td>0.52</td>
</tr>
<tr>
<td>Blood</td>
<td>10 (83.3)</td>
<td>2 (16.7)</td>
<td></td>
</tr>
<tr>
<td>Wound</td>
<td>4 (100)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Peritoneal fluid</td>
<td>1 (100)</td>
<td>0 (0)</td>
<td></td>
</tr>
</tbody>
</table>

**Table 3.** Results for β-lactamase genes in *P. aeruginosa* isolates versus demographic characteristics of patients

<table>
<thead>
<tr>
<th>Parameters</th>
<th>No. (%) of positive isolates for blaIMP gene</th>
<th>P-value</th>
<th>No. (%) of positive isolates for blaVIM gene</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean ± SD (y)</td>
<td>55.7±11.2</td>
<td>0.13</td>
<td>46.3±11.5</td>
<td>0.64</td>
</tr>
<tr>
<td>MDR</td>
<td>15 (14.7)</td>
<td>0.009</td>
<td>7 (19.4)</td>
<td>0.11</td>
</tr>
<tr>
<td>Non MDR</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>10 (32.3)</td>
<td>0.84</td>
<td>8 (25.8)</td>
<td>0.99</td>
</tr>
<tr>
<td>Female</td>
<td>5 (29.4)</td>
<td></td>
<td>4 (23.5)</td>
<td></td>
</tr>
<tr>
<td>Isolated specimen site</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine</td>
<td>10 (52.6)</td>
<td></td>
<td>4 (21.1)</td>
<td></td>
</tr>
<tr>
<td>Catheter</td>
<td>0 (0)</td>
<td></td>
<td>1 (100)</td>
<td></td>
</tr>
<tr>
<td>Tracheal aspirate</td>
<td>2 (18.2)</td>
<td>0.002</td>
<td>2 (18.2)</td>
<td>0.15</td>
</tr>
<tr>
<td>Blood</td>
<td>0 (0)</td>
<td></td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Wound</td>
<td>3 (75)</td>
<td></td>
<td>0 (0)</td>
<td></td>
</tr>
<tr>
<td>Peritoneal fluid</td>
<td>0 (0)</td>
<td></td>
<td>0 (0)</td>
<td></td>
</tr>
</tbody>
</table>
DISCUSSION

MDR Gram-negative bacteria like *P. aeruginosa* is one of the most important problems in the treatment of hospitalized patients [16]. Carbapenems are an appropriate choice for the treatment of infections with these bacteria [1]. Carbapenem-resistant *P. aeruginosa* has appeared as a global serious pathogen, but its prevalence varies by geographic region, specimen origin, patient’s age, clinical setting, and selective pressure caused by broad spectrum antibiotics [22].

The rate of resistance to carbapenems in *Pseudomonas* isolates ranged from 7.4% to 35.4% in the US during 2010. This rate varied between 18.1% in 2011 and 10.2% in 2013 among all *P. aeruginosa* isolates in ICUs of Taiwan medical centers [17].

Rates of carbapenem resistance among *P. aeruginosa* isolates in 6 European countries were more than 25%, among which Greece had the highest rate (51%) [1].

Imipenem and meropenem are regularly prescribed for the treatment of nosocomial infections caused by MDR *P. aeruginosa*, but increased resistance to these antibiotics have restricted their efficiency [16, 23].

The prevalence of imipenem resistance among *P. aeruginosa* isolates of Saudi Arabia and Egypt was about 39% [1]. A similar high rate of resistance has been reported in many developing countries throughout the world [24]. Recently, the rate of imipenem resistance in other regions of our country, such as Tehran, Ahvaz, and Hamedan has been reported to be from 11% to 61% [16].

High levels of resistance to antimicrobial agents were observed in the present research. The rate of resistance to imipenem, meropenem and ceftazidime in our *P. aeruginosa* isolates were, respectively, 97.9%, 97.9%, and 79.2%, which showed higher resistance in comparison with other studies.

This increased rate of carbapenem resistance reveals a threat, restricting medical care options in our hospitals. It can be explained partially by increased consumption of broad-spectrum antibiotics, which has caused a selective pressure of antibiotics on *P. aeruginosa* and consequently alteration of resistance mechanisms in the bacteria. Some studies reported emergence of colistin resistant organisms [17]. Our findings showed that 48.5% of isolates were resistant to colistin and a proper selection of antibiotics should be made to treat such patients.

Fig. 2. Gel electrophoresis of multiplex PCR products after amplification with specific primers for *blaIMP* gene (232 bp)
Lane 1, *blaIMP* (232 bp) positive control; lane 2, the 50 bp Ladder; lanes 3-6, clinical isolates for *blaIMP* gene; lane 7, negative control.

Fig. 3. Gel electrophoresis of multiplex PCR products after amplification with specific primers for *blaIMP* gene (232 bp) and *blaVIM* gene (391 bp)
Lane 1, the 50 bp Ladder; lane 2, *blaIMP*, *VIM* positive control; lane 3, positive clinical isolate for *blaVIM* gene; lanes 4-5, positive clinical isolates for *blaIMP* gene; lane 6, positive clinical isolate for *blaIMP* and *blaVIM* genes; lane 7, negative control.

Fig. 4. Gel electrophoresis of multiplex PCR products after amplification with specific primers for *blaVIM* gene (391 bp)
Lane 1, the 50 bp Ladder; lanes 2-5, clinical isolates for *blaVIM* gene; lane 6, *blaVIM* and *blaIMP* (232 bp) positive control; lane 7, negative control.
Therefore, administration of empirical anti-pseudomonal antibiotics, including the aminoglycosides, ticarcillin, ceftazidime, cefepime, aztreonam, the carbapenems, ciprofloxacin, and levofloxacin should be considered in patients with nosocomial infections caused by MDR *P. aeruginosa* strains [2].

Due to these different results, every institution should routinely monitor resistance rate of pathogens and antibiotics consumption, and unify the information into infection control programs [17].

Also, screening of carbapenemase producers among carbapenem-resistant *P. aeruginosa* isolates is required [19].

Phenotypic tests, such as MHT can be performed as a primary screening test to reduce the costs [18]. Carbapenemase genes were detected only in colonies, because of possible false-positive results of EDTA due to altered OprD levels; also, PCR confirmation is a gold standard [6, 12]. Fisher exact test showed a statistically significant difference between the presence of *bla*<sub>IMP</sub> gene and MDR positivity (p=0.009).

In our study, all of the 22 MHT positive cases for *VIM* and *IMP* were confirmed positive by PCR technique.

*MBLs* have been reported from many regions, from which it can be suggested that these enzymes are an important mechanism of carbapenem resistance in *P. aeruginosa*. *MBLs* belong to Ambler class B carbapenemases, and *AIM* (Adelaide imipenemase), *GIM*, *IMP*, *NDM*, *SPM*, and *VIM* types of *MBLs* have been reported worldwide [17]. Up to now different families of these enzymes have been reported from several countries, among which *IMP-* and *VIM-*producing *Pseudomonas* strains have been reported globally [25].

In our study, 44.9% of total 48 *P. aeruginosa* isolates were *MBL* producer, which was higher than the prevalence of *MBL* producers in Egyptian studies (27% and 32.3%) and Indian study (28.57%) [1].

However, the rapid spread of *MBLs*, especially among *P. aeruginosa* strains, is an emerging threat, causing nosocomial infections [20]. *MBLs* of the *IMP*, *VIM*, and *SIM* families have been mostly detected in imipenem-resistant *P. aeruginosa* strains in Iran [23].

The *VIM* enzymes are also most frequent in Korea (88%) and Greece (85%) [26]. Previous studies indicated that *IMP* and *VIM* types of *MBLs* are also prevalent in Asian countries [27-29]. *VIM* type is also highly widespread in Turkey [30]. In previous studies in Egypt (2014) and Taiwan (2013), *VIM-2* showed the highest prevalence among imipenem-resistant *P. aeruginosa* strains [1, 17].

In previous similar studies in Iran (Tehran and Sanandaj), most of the *MBL*-producing *P. aeruginosa* isolates were *bla*<sub>VIM</sub> positive and no isolate was positive for *bla*<sub>IMP</sub> gene by PCR [27]. A majority of these isolates were resistant to all β-lactam antibiotics, except monobactams [16]. In another previous study performed on burn patients in Ahvaz, 19.51% of isolates had *bla*<sub>VIM</sub> genes, but no isolate was found positive for *bla*<sub>IMP</sub> genes [31]. Our findings showed that 31.3% of isolates were *bla*<sub>IMP</sub> positive and 14.6% were *bla*<sub>VIM</sub> positive. This different prevalence of *MBL*-producing *P. aeruginosa* in Iranian studies, may be because of differences in geographic locations [23].

In this study, all isolates were negative for *bla*<sub>SME</sub>, *bla*<sub>AIM</sub>, *bla*<sub>SPM</sub>, *bla*<sub>GIM</sub>, or *bla*<sub>NDM</sub> genes by multiplex-PCR screening, which is in accordance with another similar study in sanandaj, Iran [23].

During the last decades, several types of *MBL* enzymes have been identified in *P. aeruginosa* in different countries, such as *IMP-1* that is widespread in Japan and China and is emerging in Europe and Canada [26]. There are few reports of NDM-1 in *P. aeruginosa* strains, but because of their ability to live in different environmental conditions and possibility of their spread in hospital settings, cautious vigilance and constant surveillance of these strains have been recommended [1]. Emergence of *MBL*-producing strains in health care settings can cause serious global nosocomial infections as well as problems in infection control management [16, 30, 31].

Our study has some limitations. Firstly, this was a retrospective study, and we were not able to investigate several independent factors. Secondly, although we detected the presence of *bla*<sub>VIM</sub> and *bla*<sub>IMP</sub> genes, we could not detect *AIM*, *SME*, *GIM*, *SPM*, *NDM* genes, probably because of our small sample size. Further studies are recommended to clarify if the presence of carbapenem-resistance genes can affect the clinical outcome.

Given that patients with infections caused by *MBL*-producing strains are at an increased risk of treatment failure, rapid detection of these organisms is recommended. The multiplex PCR test could complement phenotypic tests. The prevalence of *VIM* and *IMP* in the present study was relatively high and these *MBL* enzymes could emerge among hospitalized patients.

**ACKNOWLEDGEMENT**

This research has been performed with a grant from Isfahan University of Medical Sciences. The authors would like to express their gratitude to Mrs. Rezvan Shafiei, Dr. Dariush Shokri, and Mr. Mansoor Sadighi for their valuable assistance in laboratory studies of this study.

**CONFLICT OF INTEREST**

The authors declare that there are no conflicts of interest associated with this manuscript.

**REFERENCES**


